Methods of antagonizing CCK or gastrin with benzodiazepine analogs

A method of antagonizing the binding of cholecystokinins to cholecystokinin receptors or antagonizing the binding of gastrin to gastrin receptors which comprises contacting said cholecystokinin receptors or said gastrin receptors, respectively, with a compound represented by the formula:

• ##STR124## wherein R.sup.1 is H, C.sub.1 -C.sub.6 linear or branched alkyl, loweralkenyl, lower alkynyl, --X.sup.12 COOR.sup.6, --X.sup.11 -cycloloweralkyl, --X.sup.12 NR.sup.4 R.sup.5, X.sup.12 CONR.sup.4 R.sup.5, --X.sup.12 CN, or --X.sup.11 CX.sub.3.sup.10 ;
• R.sup.2 is H, loweralkyl, substituted or unsubstituted phenyl (wherein the substituents may be 1 or 2 or halo, loweralkyl, loweralkoxy, loweralkylthio, carboxyl, carboxyloweralkyl, nitro, --CF.sub.3, or hydroxy), 2-, 3-, 4-pyridyl ##STR125## R.sup.4 and R.sup.5 are independently R.sup.6 or in combination with the N of the NR.sup.4 R.sup.5 group form an unsubstituted or mono or disubstituted, saturated or unsaturated, 4-7 membered heterocyclic ring or benzofused 4-7 membered heterocyclic ring, wherein said heterocyclic ring or said benzofused heterocyclic ring may contain a second heteroatom selected from O and NCH.sub.3 and the substituent(s) is/are independently selected from C.sub.1-4 alkyl;
• R.sup.6 is H, loweralkyl, cycloloweralkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted phenylloweralkyl wherein the phenyl or phenyloweralkyl substituents may be 1 or 2 of halo, loweralkyl, loweralkoxy, nitro, or CF.sub.3 ;
• R.sup.7 is .alpha.- or .beta.-naphthyl, substituted or unsubstituted phenyl (wherein the substituents may be 1 or 2 of halo, --NO.sub.2 -- --OH, --X.sup.11 NR.sup.4 R.sup.5, loweralkyl, CF.sub.3, CN, SCF.sub.3, C.dbd.CH, CH.sub.2 SCF.sub.3, O OCCH.sub.3, OCHF.sub.2, SH, SPh, PO.sub.3 H, loweralkoxy, or loweralkylthio, COOH);
• 2-, 3-, 4-pyridyl, ##STR126## R.sup.8 is H, loweralkyl, cycloloweralkyl, --X.sup.12 CONH.sub.2, --X.sup.12 COOR.sup.6, --X.sup.12 -cycloloweralkyl, --X.sup.12 NR.sup.4 R.sup.5, ##STR127## R.sup.9 and R.sup.10 are independently H, --OH, or --CH.sub.3 ;
• R.sup.11 and R.sup.12 are independently loweralkyl or cycloloweralkyl;
• R.sup.13 is H, loweralkyl, acyl, O, or cycloloweralkyl;
• R.sup.14 is loweralkyl or phenylloweralkyl;
• R.sup.15 is H, loweralkyl, ##STR128## R.sup.16 is alpha and beta napthyl or 2-indolyl;
• R.sup.18 is H, or loweralkyl;
• p is 0 when its adjacent - - - is unsaturated and 1 when its adjacent - - - is saturated except that when R.sup.13 is 0, p=1 and is unsaturated;
• q is 0-4;
• r is 1 or 2;
• X.sup.1 is H, --NO.sub.2, CF.sub.3, CN, OH, loweralkyl, halo, loweralkylthio, loweralkoxy, --X.sup.11 COOR.sup.6, or --X.sup.11 NR.sup.4 R.sup.5 ;
• X.sup.2 and X.sup.3 are independently H, --OH, --NO.sub.2, halo, loweralkylthio, loweralkyl, or loweralkoxy;
• X.sup.4 is S, O, CH.sub.2, or NR.sup.8 ;
• X.sup.5 is H, CF.sub.3, CN, --COOR.sup.6, NO.sub.2, or halo;
• X.sup.6 is O or HH;
• X.sup.7 is O, S, HH, or NR.sup.15 with the proviso that
• X.sup.7 can be NR.sup.15 only when R.sup.1 is not H;
• X.sup.8 is H, loweralkyl;
• X.sup.9 and X.sub.a.sup.9 are independently NR.sup.18 or O;
• X.sup.10 is F, Cl, or Br;
• X.sup.11 is absent or C.sub.1-4 linear or branched alkylidene;
• X.sup.12 is C.sub.1-4 linear or branched alkylidene;
• - - - is a saturated or unsaturated bond;
• with the proviso that when X.sup.1 is Cl in the seven position, R.sup.1 is H and R.sup.2 is unsubstituted phenyl, then R.sup.3 is not NHCO(CH.sub.2).sub.2 C.sub.6 H.sub.5 or NHCOC.sub.6 H.sub.5
• and the pharmaceutically acceptable salts thereof.